Antitumor Activity of Lurbinectedin in Second-line Small Cell Lung Cancer Patients Who Are Candidates for Re-challenge with the First-line Treatment

Standard first-line chemotherapy for patients with small cell lung cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in combination with etoposide [1,2]. Recently, atezolizumab [3] or durvalumab [4] plus carboplatin/etoposide showed improved survival compared to chemotherapy alone, and both have been approved by the US FDA as first-line therapy. However, therapeutic options are limited once patients with SCLC have relapsed disease. The National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO) guidelines recommend re-challenge with the first-line regimen in relapsed SCLC patients with sensitive disease, defined as patients with a chemotherapy-free interval (CTFI) ≥90 days in the ESMO guidelines and patients with a CTFI ≥ 180 days in the NCCN guidelines [1,2].

Source: Lung Cancer - October 9, 2020 Category: Cancer & Oncology Authors: Vivek Subbiah, Luis Paz-Ares, Benjamin Besse, Victor Moreno, Solange Peters, Mar ía Angeles Sala, José Antonio López-Vilariño, Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Ali Zeaiter, Khalil Zaman, Rafael López, Santiago Ponc Source Type: research